454 Revenues Pick Up in Q3, But Roche's Overall Genomic Sales Decline 12 Percent Year to Date | GenomeWeb

By Julia Karow

This story was originally published Oct. 17.

Revenues of Roche's 454 Life Sciences unit increased in the third quarter compared to the second, while sales for Roche Applied Science's genomic analysis business, which comprises both 454 and Roche NimbleGen, declined 12 percent in local currencies during the first nine months of 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.